0000950170-23-073306.txt : 20231227
0000950170-23-073306.hdr.sgml : 20231227
20231227161511
ACCESSION NUMBER: 0000950170-23-073306
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231222
FILED AS OF DATE: 20231227
DATE AS OF CHANGE: 20231227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DiPietro Kenneth
CENTRAL INDEX KEY: 0001540188
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39311
FILM NUMBER: 231518098
MAIL ADDRESS:
STREET 1: C/O BIOGEN IDEC INC.
STREET 2: 133 BOSTON POST ROAD
CITY: WESTON
STATE: MA
ZIP: 02493
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001805387
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 844-304-2048
MAIL ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II
DATE OF NAME CHANGE: 20200303
4
1
ownership.xml
4
X0508
4
2023-12-22
0001805387
Cerevel Therapeutics Holdings, Inc.
CERE
0001540188
DiPietro Kenneth
C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
222 JACOBS STREET, SUITE 200
CAMBRIDGE
MA
02141
false
true
false
false
Chief Human Resources Officer
false
Common Stock
2023-12-22
4
M
false
8000
3.50
A
32663
D
Common Stock
2023-12-22
4
S
false
8000
41.4510
D
24663
D
Stock Option (Right to Buy)
3.50
2023-12-22
4
M
false
8000
0.00
D
2029-04-02
Common Stock
8000
302242
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.45 to $41.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option is fully vested and exercisable.
/s/ Mark Bodenrader, as Attorney-in-Fact
2023-12-27